Richard Shea
Director/Board Member chez SYNLOGIC, INC.
Fortune : 895 $ au 31/03/2024
Profil
Richard P.
Shea is currently a Director at Synlogic Operating Co., Inc. and an Independent Director at Synlogic, Inc. He previously worked as Vice President-Finance at Genetics Institute LLC from 1992 to 1999, Chief Operating & Financial Officer at Variagenics, Inc. from 1999 to 2003, Chief Financial Officer & Senior Vice President at Momenta Pharmaceuticals, Inc. from 2015 to 2016, and CFO, Treasurer & Principal Accounting Officer at Syndax Pharmaceuticals, Inc. from 2017 to 2020.
Mr. Shea holds an MBA from Boston University and an undergraduate degree from Princeton University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNLOGIC INC
0,00% | 18/08/2023 | 500 ( 0,00% ) | 895 $ | 31/03/2024 |
Postes actifs de Richard Shea
| Sociétés | Poste | Début |
|---|---|---|
| SYNLOGIC, INC. | Director/Board Member | 28/08/2017 |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Anciens postes connus de Richard Shea
| Sociétés | Poste | Fin |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Director of Finance/CFO | 13/07/2020 |
| MOMENTA PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/12/2016 |
Variagenics, Inc.
 Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Director of Finance/CFO | 01/04/2003 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 01/01/1999 |
Formation de Richard Shea
| Boston University | Masters Business Admin |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Commercial Services |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
| Synlogic, Inc. |
